Get the Stockscreener App
1.38
1.43%
-0.02
After Hours:
1.36
-0.02
-1.45%
IO Biotech Inc stock is currently priced at $1.38, with a 24-hour trading volume of 53,166.
It has seen a -1.43% decreased in the last 24 hours and a -8.00% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.40 pivot point. If it approaches the $1.37 support level, significant changes may occur.
Previous Close:
$1.40
Open:
$1.42
24h Volume:
53,166
Market Cap:
$90.92M
Revenue:
-
Net Income/Loss:
$-86.08M
P/E Ratio:
-0.537
EPS:
-2.57
Net Cash Flow:
$-72.06M
1W Performance:
-3.50%
1M Performance:
-8.00%
6M Performance:
+38.79%
1Y Performance:
-32.02%
1D Range:
$1.36
$1.48
52W Range:
$0.8163
$2.28
IO Biotech Inc Stock (IOBT) Company Profile
Name
IO Biotech Inc
Sector
Industry
Phone
45 70 70 29 80
Address
Ole Maaløes Vej 3, Copenhagen N, Copenhagen
IO Biotech Inc Stock (IOBT) Latest News
HC Wainwright Increases IO Biotech (NASDAQ:IOBT) Price Target to $12.00 - Defense World
Defense World
IO Biotech, Inc. to Post Q2 2024 Earnings of ($0.31) Per Share, HC Wainwright Forecasts (NASDAQ:IOBT) - Defense World
Defense World
Honey Badger Silver (CVE:TUF) Shares Up 21.4% After Insider Buying Activity - Defense World
Defense World
Q2 2024 EPS Estimates for IO Biotech, Inc. Raised by HC Wainwright (NASDAQ:IOBT) - MarketBeat
MarketBeat
IO Biotech, Inc. (NASDAQ:IOBT) Major Shareholder Holdings A/S Novo Sells 658809 Shares - Defense World
Defense World
Swiss National Bank Sells 3500 Shares of CSW Industrials, Inc. (NASDAQ:CSWI) - Defense World
Defense World
IO Biotech Inc Stock (IOBT) Financials Data
IO Biotech Inc (IOBT) Net Income 2024
IOBT net income (TTM) was -$86.08 million for the quarter ending December 31, 2023, a -20.47% decrease year-over-year.
IO Biotech Inc (IOBT) Cash Flow 2024
IOBT recorded a free cash flow (TTM) of -$72.06 million for the quarter ending December 31, 2023, a -19.27% decrease year-over-year.
IO Biotech Inc (IOBT) Earnings per Share 2024
IOBT earnings per share (TTM) was -$2.1574 for the quarter ending December 31, 2023, a +13.01% growth year-over-year.
IO Biotech Inc Stock (IOBT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Novo Holdings A/S | 10% Owner |
Feb 09 '24 |
Sale |
1.50 |
658,809 |
988,411 |
5,088,258 |
| Burkavage Brian | Chief Accounting Officer |
Nov 22 '23 |
Buy |
1.03 |
5,000 |
5,175 |
11,500 |
| Burkavage Brian | Chief Accounting Officer |
Nov 21 '23 |
Buy |
0.99 |
5,000 |
4,950 |
6,500 |
| Vivo Capital IX, LLC | 10% Owner |
Aug 09 '23 |
Buy |
1.90 |
3,157,894 |
5,999,999 |
3,157,894 |
| Novo Holdings A/S | 10% Owner |
Aug 09 '23 |
Buy |
2.02 |
2,469,135 |
4,999,998 |
5,707,467 |
About IO Biotech Inc
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
0.77%
1.20%
Cap:
|
Volume (24h):